- Oops!Something went wrong.Please try again later.
DGAP-News: Gerresheimer AG / Key word(s): Quarterly / Interim Statement/Half Year Report
Duesseldorf, July 13, 2021 - Gerresheimer AG showed strong revenue growth in the second quarter of 2021. "The new company focus on sustainable growth, innovation and providing solutions for our customers is bearing fruits. We revealed our strengths in the second quarter. Prefillable syringes and other high-value solutions such as for biotech drugs are the main drivers. The delivery of injection vials is running as planned. We expect a strong second half of the year and confirm our guidance for 2021," says Dietmar Siemssen, CEO of Gerresheimer AG.
Adjusted EBITDA in the core business stood at EUR 85 million, corresponding to an organic growth of 3.1 %. The organic adjusted EBITDA margin in the core business amounted to 22.8 %. Adjusted net income stood at EUR 41 million. Adjusted earnings per share stood at EUR 1.28, which is a year-on-year increase of 19.1 %.
Medium term (core business, net of currency effects):
The Quarterly Statement for the second quarter of 2021 is available here:
Investor Relations contact
Key Figures for the Gerresheimer Group
13.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID:
End of News
DGAP News Service